Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of Medicine ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

How Long Does It Take for Semaglutide to Work? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide is the active ingredient in the weight loss medication Wegovy and the ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...